Apellis Pharmaceuticals granted restricted stock units to new employee outside of stock incentive plan.

From Globe Newswire: 2024-10-04 16:05:00

Apellis Pharmaceuticals granted one new employee 4,240 restricted stock units on October 1, 2024, as an equity inducement award outside of the company’s 2017 Stock Incentive Plan. Each RSU will vest annually based on continued employment. Apellis focuses on developing therapies for challenging diseases, including the first-ever therapy for geographic atrophy. The company is optimistic about the potential of targeting C3 in various serious conditions. Concerning forward-looking statements, Apellis cautions investors about potential risks. For media inquiries, contact Tracy Vineis at [email protected]. For investor relations, reach out to Meredith Kaya at [email protected].



Read more at Globe Newswire: Apellis Pharmaceuticals Announces Inducement Grants Under